For the full year 2023, Biogen is reaffirming its guidance for total revenue to decline a mid-single digit percentage versus reported full year 2022, consensus $9.56B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
- Biogen price target raised to $300 from $295 at BofA
- Agios Pharmaceuticals appoints Capello to board of directors
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Biogen price target raised to $320 from $315 at Argus